1529 related articles for article (PubMed ID: 17541913)
21. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
22. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
23. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
24. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
Nagel H; Hemmerlein B; Ruschenburg I; Hüppe K; Droese M
Pathol Res Pract; 1998; 194(11):759-64. PubMed ID: 9842634
[TBL] [Abstract][Full Text] [Related]
25. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
[TBL] [Abstract][Full Text] [Related]
26. The role of immunohistochemistry in the diagnosis of neoplastic pleural effusions.
Dinu M; Ciurea RN; Stefan M; Georgescu AC
Rom J Morphol Embryol; 2012; 53(3 Suppl):817-20. PubMed ID: 23188446
[TBL] [Abstract][Full Text] [Related]
27. Ten cases of feline mesothelioma: an immunohistochemical and ultrastructural study.
Bacci B; Morandi F; De Meo M; Marcato PS
J Comp Pathol; 2006 May; 134(4):347-54. PubMed ID: 16712862
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
29. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
30. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
Cakir C; Gulluoglu MG; Yilmazbayhan D
Pathology; 2006 Feb; 38(1):10-5. PubMed ID: 16484001
[TBL] [Abstract][Full Text] [Related]
31. [Small-cell mesothelioma of the pleura: description of a case].
Cavazza A; Rossi G; Agostini L; Facciolongo N; De Marco L; Putrino I; Gardini G
Pathologica; 2002 Oct; 94(5):247-52. PubMed ID: 12417972
[TBL] [Abstract][Full Text] [Related]
32. Distinction between carcinoma cells and mesothelial cells in serous effusions. Usefulness of immunohistochemistry.
Tickman RJ; Cohen C; Varma VA; Fekete PS; DeRose PB
Acta Cytol; 1990; 34(4):491-6. PubMed ID: 2197840
[TBL] [Abstract][Full Text] [Related]
33. Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases.
Galateau-Sallé F; Attanoos R; Gibbs AR; Burke L; Astoul P; Rolland P; Ilg AG; Pairon JC; Brochard P; Begueret H; Vignaud JM; Kerr K; Launoy G; Imbernon E; Goldberg M
Am J Surg Pathol; 2007 May; 31(5):711-6. PubMed ID: 17460454
[TBL] [Abstract][Full Text] [Related]
34. My approach to the diagnosis of mesothelial lesions.
Butnor KJ
J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
[TBL] [Abstract][Full Text] [Related]
35. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
36. Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
Kimura F; Kawamura J; Watanabe J; Kamoshida S; Kawai K; Okayasu I; Kuwao S
Diagn Cytopathol; 2010 Mar; 38(3):161-7. PubMed ID: 19821496
[TBL] [Abstract][Full Text] [Related]
37. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
Saad RS; Cho P; Liu YL; Silverman JF
Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
[TBL] [Abstract][Full Text] [Related]
38. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
Dejmek A; Hjerpe A
Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
[TBL] [Abstract][Full Text] [Related]
39. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
40. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
